Drug Profile


Alternative Names: ACE910; Anti-factor IXa x anti-factor X humanized bispecific antibody; RG 6013; RO 5534262

Latest Information Update: 04 May 2017

Price : $50

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Chugai Pharmaceutical; Roche
  • Class Antihaemorrhagics; Bispecific antibodies; Monoclonal antibodies; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Haemophilia A

Most Recent Events

  • 17 Apr 2017 Interim efficacy and adverse events data from the phase III HAVEN 2 trial in Haemophilia A (In children, In infants) released by Roche
  • 01 Jan 2017 Roche and Chugai re-initiates enrolment in a phase III trial for Hemophilia A (In adolescent, In adult, In children) in Spain and Japan (EudraCT2016-001094-33)
  • 22 Dec 2016 Adverse events data from the phase III HAVEN 1 trial in Haemophilia A (In adolescents, In adults) released by Genentech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top